跳到正文
制药经理人· GxP知识岛·· 12 天前同事件AI 评分83

FDA发布印度USV制药达曼工厂警告信,指无菌灌装线设计缺陷与目视检查不足

FDA警告信:设计缺陷无法通过验证消除,必须重新设计!

AI 导读

FDA向印度USV Private Limited(FEI 3004086192)达曼工厂发布警告信,列出无菌工艺与目视检查等CGMP违规。2026年4月7日至17日检查发现,ISO 5西林瓶灌装线烟雾试验未呈现单向流、本意作为RABS的灌装线存在重大设计缺陷,FDA认为此类固有缺陷无法通过验证消除、必须重新设计。

同一件事,精选收录的是《FDA 向 USV Private Limited 达贝厂发出警告信,指无菌灌装与可见颗粒物检查违反 CGMP》

正文

近日,FDA发布了印度USV制药公司(USV Private Limited,下称USV)的警告信。其中提及无菌保证缺陷。包括ISO 5西林瓶灌装线的烟雾试验未呈现单向流,气流出现涡旋并向上流动;本意作为限制进入屏障系统(RABS)的灌装线存在重大设计缺陷;操作人员把前臂伸到无菌设备上方,破坏第一气流。FDA在警告信中表示:该公司无菌工艺操作在设计上存在根本缺陷,导致单向流不足、人机工效不佳和无菌操作不当。此类固有缺陷无法通过验证消除,必须重新设计。

翻译如下:

To Mr. Jayant Dwivedy:

致 Jayant Dwivedy 先生:

This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.

本警告信告知你司:FDA在你司设施的检查中观察到重大违规,并给予你司说明和处理的机会。请立即处理本信所述任何违规,不得拖延,包括确保分配适当资源以全面处理并防止其再次发生。本信并非你司设施现有违规的完整清单。确保你司符合联邦法律(包括FDA法规)的全部要求,是你司的责任。未充分处理任何违规,可能导致FDA在不另行通知的情况下采取监管行动。

FDA Inspection

FDA现场检查

Violations were observed and documented during an inspection of your drug manufacturing facility, USV Private Limited, FDA Establishment Identifier (FEI) 3004086192, at H-13, 16, 16a, 17, 18, 19, 20, 21 & E-22, OIDC Mahatma Gandhi Udyog Nagar, Dabhel, Daman, Dadra and Nagar Haveli and Dam, from April 7 to 17, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.

在对你司药品生产设施——USV Private Limited(FDA企业识别号FEI 3004086192,地址:印度达曼(Daman)Dabhel,OIDC圣雄甘地工业园(Mahatma Gandhi Udyog Nagar),H-13、16、16a、17、18、19、20、21及E-22)2026年4月7日至17日的检查中,观察并记录了违规。本次检查依据FDA的法定权限和公共卫生职责进行,目的是保护公众免受不安全、无效和劣质药品的危害。

This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).

本警告信概述成品药现行药品生产质量管理规范(CGMP)法规的重大违规。见《美国联邦法规》第21篇第210、211部分(21 CFR 210、211)。

Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).

由于你司生产、加工、包装或贮存的方法、设施或控制措施不符合CGMP,你司药品属于FD&C法案第501(a)(2)(B)条(21 U.S.C. 351(a)(2)(B))所指的掺假药品。

We reviewed your May 8, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.

我方详细审阅了你司2026年5月8日对FDA 483表的回复,并确认收到你司后续来函。

Violations of the Federal Food, Drug, and Cosmetic Act

FD&C法案项下的违规

The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.

以下为本次检查及审阅中发现的违规。再次提醒,这不是你司设施全部违规的完整清单。

1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).

1. 你司未建立并遵守适当的书面程序,以防止宣称无菌的药品受到微生物污染,且程序未包含对所有无菌工艺和灭菌工艺的验证(21 CFR 211.113(b))。

Your firm manufactures aseptically filled parenteral (b)(4) drug products. You failed to implement appropriate processes and systems to assure an ongoing state of control of your aseptic processing operations.

你司生产无菌灌装的注射用(b)(4)药品。你司未能实施适当的工艺和系统,以确保无菌工艺操作处于持续受控状态。

You aseptically manufacture injectable products using a (b)(4) approach, with (b)(4). In addition, your (b)(4) filling line included (b)(4) and was intended as a restricted access barrier system (RABS) but had significant design deficiencies.

你司采用(b)(4)方式无菌生产注射剂,并(b)(4)。此外,你司(b)(4)灌装线包含(b)(4),本意作为限制进入屏障系统(RABS),但存在重大设计缺陷。

Your airflow visualization studies (i.e., smoke studies) performed for the ISO 5 vial filling line did not exhibit unidirectional airflow throughout the ISO 5 area. This lack of unidirectional airflow poses a significant risk to drug product sterility. For example, airflow was observed to swirl and move upward. Additionally, your smoke studies did not adequately evaluate airflow at ISO 5 to ISO 7 transition interfaces.

你司对ISO 5西林瓶灌装线所做气流可视化研究(即烟雾试验),未能在整个ISO 5区域呈现单向流。单向流缺失对药品无菌性构成重大风险。例如,观察到气流出现涡旋并向上流动。此外,你司的烟雾试验未充分评估ISO 5至ISO 7过渡界面的气流。

We also observed poor aseptic technique during (b)(4) interventions on your (b)(4) filling lines. For example, operators breached first air by extending their forearms over sterile equipment. Additionally, there was inadequate control of material flow from ISO 7 to ISO 5 areas.

我方还观察到,在你司(b)(4)灌装线进行(b)(4)干预时,无菌操作技术不佳。例如,操作人员将前臂伸到无菌设备上方,破坏了第一气流(first air)。此外,从ISO 7到ISO 5区域的物流控制不足。

In your response, you acknowledge deficiencies in your aseptic practices and airflow visualization studies. You add that you engaged an independent consultant to advise on these areas. However, your retrospective risk assessment concluded that the process was in a state of control, citing “no growth” (b)(4) monitoring and compliant environmental monitoring for the (b)(4) filling line. You also cite compliant sterility and bacterial endotoxin results for the vial filling line, and passing media fills for (b)(4) lines.

你司在回复中承认无菌操作和气流可视化研究存在缺陷,并称已聘请独立顾问就这些方面提供建议。但你司的回顾性风险评估结论是工艺处于受控状态,依据是(b)(4)灌装线(b)(4)监测“无生长”以及环境监测符合要求;你司还援引西林瓶灌装线无菌和细菌内毒素结果合格,以及(b)(4)线培养基灌装通过。

Your response is inadequate. The aseptic processing operations have fundamental flaws in design leading to unidirectional airflow deficiencies, poor ergonomics, and deficient aseptic practices. Such inherent flaws cannot be validated and necessitate redesign. While you engaged consultants for specific aspects of your process design and smoke study program, you lack sufficient commitment to comprehensively remediate your aseptic processing operations, supported by a complete assessment of your aseptic processing operation and equipment replacement. Your risk assessment relies on proxy indicators such as sterility results, media fill pass rates, and environmental monitoring data without systematically addressing deficiencies in the design and control of your operation.

你司回复不充分。无菌工艺操作在设计上存在根本缺陷,导致单向流不足、人机工效不佳和无菌操作不当。此类固有缺陷无法通过验证消除,必须重新设计。尽管你司就工艺设计和烟雾试验程序的特定方面聘请了顾问,但缺乏全面整改无菌工艺操作的充分承诺,也未提供完整的无菌工艺操作评估和设备更换方案。你司的风险评估依赖无菌结果、培养基灌装通过率和环境监测数据等替代指标,却未系统解决操作设计与控制方面的缺陷。

The ISO 5 area is critical because sterile products are exposed and therefore vulnerable to contamination. Your aseptic manufacturing process should be designed, and operations executed to prevent contamination hazards to your sterile product.

ISO 5区域至关重要,因为无菌产品在此暴露,易受污染。你司的无菌生产工艺应按防止无菌产品受到污染风险的要求进行设计,并按此执行操作。

In your response to this letter, provide:

请在回复本信时提供:

· Your systematic plan to assure adherence to appropriate aseptic practices, cleanroom behavior, and written procedures, including but not limited to an independent assessment of the following with accompanying corrective action and preventive action (CAPA):

· 确保遵守适当无菌操作、洁净室行为和书面程序的系统性计划,包括但不限于对以下各项的独立评估及相应纠正与预防措施(CAPA):

○ Suitability of actual practices based on extensive retrospective review and prospective observation of aseptic processing operations

○ 基于对无菌工艺操作的大范围回顾性审查和前瞻性观察,评估实际操作是否适当

○ Deficiencies in production management oversight, and identification of specific improvements to ensure effective and routine supervisory oversight for all batches

○ 生产管理监督的缺陷,并明确具体改进措施,以确保对所有批次实施有效且常规的监督

○ Frequency and depth of quality unit (QU) oversight (e.g., audit, ad hoc, daily interactions) of aseptic processing and its support operations

○ 质量部门(QU)对无菌工艺及其支持性操作的监督频率与深度(如审计、临时检查、日常沟通)

○ Adequacy of written procedures and operational ergonomics

○ 书面程序和人机工效是否适当

○ The assessment should also evaluate how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs

○ 该评估还应评价无菌操作不当和洁净室行为不当可能对你司药品质量和无菌性造成的影响

· Describe whether all personnel performing activities that take place in ISO 5 areas are held to ISO 5 personnel monitoring standards

· 说明在ISO 5区域从事活动的所有人员是否均按ISO 5人员监测标准进行监测

2. Your firm failed to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups. Your firm also failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance. (21 CFR 211.42(c) and 21 CFR 211.63).

2. 你司未设置单独的或划定的区域,或未建立防止污染或混淆所需的其他控制系统。你司也未在药品生产、加工、包装或贮存中使用设计适当、尺寸足够且位置适宜、便于按其预期用途操作以及清洁和维护的设备。(21 CFR 211.42(c) 与 21 CFR 211.63)

Your facilities and equipment are not adequately designed to protect sterile drugs from significant contamination risks. In addition to areas of deficiency described in the first violation in this letter, other examples include:

你司设施和设备的设计不足以保护无菌药品免受重大污染风险。除本信第一条违规所述缺陷区域外,其他例子包括:

· The (b)(4) filling line’s (b)(4) conveyor system physically blocked continuous ISO 5 unidirectional airflow from reaching open sterile bottles during transport to the filling station.

· (b)(4)灌装线的(b)(4)输送系统在向灌装工位传送过程中,物理阻挡了连续的ISO 5单向流到达敞口无菌瓶。

· Critical areas used for aseptic connections, sterile component unwrapping, and material transfers were insufficient to assure maintenance of ISO 5 conditions.

· 用于无菌连接、无菌组件拆包和物料传递的关键区域,不足以确保维持ISO 5状态。

· Significant turbulence was observed in your vial filling line airflow visualization videos. However, your firm concluded that airflow was adequate.

· 在西林瓶灌装线气流可视化视频中观察到明显湍流,但你司仍判定气流充分。

Your initial response indicates that you suspended production on the (b)(4) line, pending engineering assessment and remediation. However, your remediations are minor and narrow in scope. Your response is inadequate because it fails to address the need for comprehensive remediation across your aseptic processing operations.

你司初次回复称,已暂停(b)(4)线生产,等待工程评估和整改。但你司的整改措施轻微且范围狭窄。该回复不充分,因为它未解决在整个无菌工艺操作范围内进行全面整改的需要。

In your response to this letter, provide:

请在回复本信时提供:

· Comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:

· 针对你司无菌工艺、设备和设施的所有污染风险开展全面、独立的风险评估,包括但不限于:

○ All human interactions within the ISO 5 area (e.g., risk reduction or elimination of (b)(4) interventions wherever possible)

○ ISO 5区域内的所有人工干预(例如尽可能降低或消除(b)(4)干预)

○ Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space

○ 设备适用性(如可靠性、能力、人机工效、摆放位置)和足够的洁净室空间

○ Air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow

○ ISO 5区域及周边房间的空气质量,包括但不限于风量与气流

○ Facility layout

○ 设施布局

○ Personnel Flow and Material Flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers)

○ 人员流向和物流(在用于实施和支持无菌操作的所有房间内的移动,以及所有物料传递)

○ Specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment

○ 能够全面解决风险评估中所识别设计与控制风险的具体CAPA建议

○ A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.

○ 针对污染风险评价结论的详细整改计划及时间表。说明你司设施无菌工艺操作设计与控制将做出的具体、实质性改进,并解释该CAPA计划如何有力整改存在缺陷的无菌生产操作。包括对无菌工艺线和洁净室设计的全面变更。同时说明对经大幅整改的操作进行确认和验证的计划。

○ Also describe your contingency plans in the event your supply chain continuity may be compromised (e.g., stockpiling inventory using interim manufacturing controls, and/or utilizing contract manufacturing organizations).

○ 此外,说明在供应链连续性可能受到影响时的应急预案(例如采用临时生产控制措施储备库存,和/或使用受托生产企业)。

· An independent, comprehensive evaluation of airflow unidirectionality in your aseptic processing operations. Ensure smoke studies are conducted under dynamic conditions with thorough and complete evaluations of aseptic processing line airflow unidirectionality, including special emphasis on the impact of aseptic interventions and dynamic interactions with the surrounding cleanroom. Conduct these smoke studies after you remediate your aseptic operation and using proper practices (e.g., neutrally buoyant media) to appropriately visualize airflow.

· 对你司无菌工艺操作中气流单向性开展独立、全面的评价。确保烟雾试验在动态条件下进行,对无菌工艺线气流单向性作出彻底、完整的评价,特别强调无菌干预的影响以及与周边洁净室的动态相互作用。在完成无菌操作整改后,采用适当做法(如中性浮力介质)开展这些烟雾试验,以恰当可视化气流。

· For your aseptic processing rooms, provide detailed description of the current location of each air return, including but not limited to any located on or near the ceiling. Describe in detail the air flow dynamics at each return and provide any related smoke studies.

· 针对你司无菌工艺房间,详细说明每个回风口的当前位置,包括但不限于位于天花板之上或附近的回风口。详细描述每个回风口气流动力学,并提供相关烟雾试验。

· Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should incorporate oversight from a qualified independent consultant and ensure, among other things, prompt detection of equipment/facilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment/facility infrastructure, and improved systems for senior management review. Your plan should also ensure that appropriate actions are taken throughout the company network.

· 你司对设施和设备实施常规、警觉的运营管理监督的CAPA计划。该计划应纳入合格独立顾问的监督,并确保(其中包括)及时发现设备/设施性能问题、有效执行维修、遵守适当的预防性维护计划、及时进行设备/设施基础设施的技术升级,以及改进高层管理评审体系。该计划还应确保在整个公司网络内采取适当措施。

3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).

3. 你司未建立实验室控制,包括科学合理且适当的质量标准、标准、取样计划和检验程序,以确保组分、药品容器、密封件、中间物料、标签和药品符合适当的鉴别、含量、质量和纯度标准(21 CFR 211.160(b))。

Your visual inspection program was inadequate to assure your drug products were essentially free of visible particulates.

你司的目视检查程序不足以确保药品基本不含可见异物。

Lack of Alert and Action Limits

缺乏警戒限和行动限

You lacked action limits for visible particulates. You also only defined alert limits for certain particulate types in selected presentations of your (b)(4) injection drug products. Your visual inspection procedure requires the investigation of atypical trends, yet you failed to investigate atypical trends in (b)(4) injection batch (b)(4). Without well-defined metrics to characterize acceptable process performance, including but not limited to alert and action limits, it is difficult to reliably detect when a process has deviated from a state of control.

你司对可见异物未设行动限。对(b)(4)注射剂部分规格的某些异物类型,你司仅设定了警戒限。你司目视检查程序要求对异常趋势进行调查,但你司未对(b)(4)注射剂批次(b)(4)中的异常趋势进行调查。缺乏用于表征可接受工艺性能的明确指标(包括但不限于警戒限和行动限),就难以可靠地发现工艺何时偏离受控状态。

Lack of Extrinsic and Intrinsic Particulate Classification

未区分外源性与内源性异物

You did not classify particulates as extrinsic or intrinsic. However, your procedures state that extrinsic particulates indicating filth, sterility assurance issues, or CGMP violations are unacceptable irrespective of statistical sampling acceptance criteria. Your failure to classify extrinsic particles from your batches can lead to not detecting critical quality and safety risks.

你司未将异物区分为外源性或内源性。但你司程序规定,表明污物、无菌保证问题或CGMP违规的外源性异物,无论统计抽样接受标准如何,均不可接受。你司未对批次中的外源性粒子进行分类,可能导致无法发现关键的质量和安全风险。

Prior to March 28, 2026, you also released all batches of (b)(4) without adequate visible particulate assessment.

2026年3月28日之前,你司还在未进行充分可见异物评估的情况下放行了所有(b)(4)批次。

In your response, you commit to establish alert and action limits for all products. You also commit to implement intrinsic and extrinsic particulate classifications, and a destructive testing program for (b)(4) containers (such as those used for (b)(4). You state that retrospective destructive testing of (b)(4) batches within expiry did not detect any particles.

你司在回复中承诺为所有产品建立警戒限和行动限,并承诺实施内源性与外源性异物分类,对(b)(4)容器(例如用于(b)(4)的容器)实施破坏性试验程序。你司称,对有效期内(b)(4)批次进行的回顾性破坏性试验未检出粒子。

Your response is inadequate. It does not address your failure to follow your own procedures on batch disposition criteria for extrinsic particles for products already distributed. Moreover, retrospective destructive testing and assessments of flawed visual inspection data cannot substitute for the required characterization and control you lacked at the time of production.

你司回复不充分。它未解决你司对已销售产品的外源性异物批处置标准未遵守自身程序的问题。此外,回顾性破坏性试验和对有缺陷目视检查数据的评估,不能替代生产当时所缺失的必要表征与控制。

In response to this letter, provide:

请在回复本信时提供:

· Raw data and tabulated summary of your retrospective destructive testing results

· 回顾性破坏性试验的原始数据和汇总表

· An independent, comprehensive assessment and remediation plan for your visual inspection program to ensure compliance with CGMP. The remediation plan should incorporate USP <790> Visible Particulates in Injections (b)(4), including container-specific testing protocols (e.g., (b)(4) containers) for each container type. Your strategy should include:

· 对目视检查程序开展独立、全面的评估和整改计划,以确保符合CGMP。整改计划应纳入USP<790>《注射剂中的可见异物》(b)(4),包括针对每种容器类型的容器专属检验方案(例如(b)(4)容器)。你司策略应包括:

○ For all products, assess the suitability of all specifications, alert and action limits, sampling methods, test methods, and validation for visible particulate inspection, subvisible particulate inspection, as well as any supplemental destructive tests, to determine if they are sufficient to support batch disposition decisions. The assessment should also identify appropriate CAPAs, including these elements:

○ 对全部产品,评估所有质量标准、警戒限与行动限、取样方法、检验方法和验证是否适用于可见异物检查、亚可见异物检查以及任何补充性破坏性试验,判定其是否足以支持批处置决定。该评估还应确定适当的CAPA,包括以下要素:

▪ Enhancements to your 100% visible particulate inspection practices to improve detectability and reliability

▪ 改进100%可见异物检查做法,提高可检出性和可靠性

▪ Robust methods, equipment, and personnel qualifications to reproducibly detect visible particulates

▪ 采用稳健的方法、设备和人员资质确认,以可重现地检出可见异物

▪ Rigorous qualification studies to ensure your (b)(4) visible particulate inspection systems consistently and reproducibly detect the variety of visible particulates encountered in your drug products

▪ 开展严格的确认研究,确保你司(b)(4)可见异物检查系统能够一致、可重现地检出药品中遇到的各类可见异物

▪ Review past history to develop a product-specific, risk-based visual inspection approach incorporating product knowledge, process experience, deviation investigation analysis, historical data on particle contaminants and sources, and recall/complaint data to ensure ongoing compliance with USP <790>, (b)(4), and CGMP requirements

▪ 回顾历史情况,制定针对具体产品、基于风险的目视检查方法,纳入产品知识、工艺经验、偏差调查分析、粒子污染物及其来源的历史数据,以及召回/投诉数据,以确保持续符合USP<790>、(b)(4)和CGMP要求

○ If you manufacture difficult-to-inspect products (e.g., (b)(4) containers), address these elements and provide a CAPA:

○ 如你司生产难以检查的产品(例如(b)(4)容器),应针对这些要素作出说明并提供CAPA:

▪ 100% visible inspection using enhanced lighting with background contrast methods, as appropriate (e.g., (b)(4) containers (b)(4)) that optimize visual inspection

▪ 采用增强照明并配合背景反差方法的100%可见异物检查(视情况,例如(b)(4)容器(b)(4)),以优化目视检查

▪ Identify provisions for highly capable supplemental destructive testing and/or use of advanced technologies (e.g., (b)(4)), as appropriate, with statistically significant sample sizes to test for critical defects.

▪ 确定高能力补充性破坏性试验和/或使用先进技术(例如(b)(4))的安排,视情况采用具有统计学意义的样本量检验关键缺陷。

○ If you manufacture drug products that preclude visual particulate inspection (e.g., products packaged in (b)(4) containers), address these elements and provide a CAPA:

○ 如你司生产的药品无法进行可见异物目视检查(例如包装于(b)(4)容器中的产品),应针对这些要素作出说明并提供CAPA:

▪ Highly capable destructive testing method(s), with appropriate, statistically significant sample sizes to test for particulates.

▪ 采用高能力破坏性检验方法,并配以适当、具有统计学意义的样本量进行异物检验。

○ In each case, whenever visual inspection methods are insufficient or cannot be used, also implement enhanced upstream particulate controls (e.g., in-process (b)(4), environmental controls, protective design provisions, robust container/closure supplier oversight). This should also generally include appropriate in-process visible particulate matter testing at (b)(4) stage.

○ 在上述每种情况下,凡目视检查方法不足或无法使用时,还应实施强化的上游异物控制(例如过程内(b)(4)、环境控制、防护性设计措施、对容器/密封件供应商的严格监督)。这通常还应包括在(b)(4)阶段开展适当的过程内可见异物检验。

○ A risk assessment of all previously released batches currently within expiry that were released without adequate evaluation of particulate contamination.

○ 对目前在有效期内、且在放行时未充分评估异物污染的所有既往批次开展风险评估。

· A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, action level results (out of limits), and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.

· 对你司调查偏差、差异、投诉、超标结果、警戒限结果(超限)和失败的总体体系开展全面、独立的评估。提供整改该体系的详细行动计划。该行动计划应包括但不限于在调查能力、范围确定、根本原因评价、CAPA有效性、质量部门监督和书面程序方面的重大改进。说明你司将如何确保调查各阶段均得到适当开展。

· A comprehensive assessment and remediation plan to ensure your QU is given the authority, independence, and resources to effectively function that includes, but is not limited to:

· 确保你司质量部门获得有效履职所需权限、独立性和资源的全面评估与整改计划,包括但不限于:

○ A determination of whether procedures used by your firm are robust and appropriate

○ 判定你司所用程序是否稳健、适当

○ Provisions for independent QU oversight throughout your operations to ensure satisfactory procedures and adherence to appropriate practices

○ 在全部运营环节为质量部门提供独立监督安排,以确保程序令人满意并符合适当规范

○ A complete and final review of each batch and its related information before the QU disposition decision

○ 在质量部门作出处置决定前,对每个批次及其相关信息进行完整、最终审核

○ Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products

○ 对调查进行监督和批准,并履行质量部门其他全部职责,以确保所有产品的鉴别、含量、质量和纯度

○ Also, describe how executive management will support robust quality assurance at your firm, including but not limited to timely provision of resources that enable proactive detection and resolution of emerging manufacturing/quality issues to assure a continuing state of control

○ 此外,说明高层管理将如何支持你司稳健的质量保证,包括但不限于及时提供资源,以便主动发现和解决新出现的生产/质量问题,确保持续受控状态

Visible Particulate Contamination

可见异物污染

We encourage the use of suitable (b)(4) visual inspection for particulates to augment the (b)(4) visual inspection program. (b)(4) methods should be rigorously studied, and qualified, to assess their capability and robustness under various conditions, machine settings, container-closure sizes, defect types, product characteristic, and other variables. In addition, any use of (b)(4) particulate inspection as an adjunct method does not supplant the need for (b)(4) visual inspection for various other attributes (e.g., cracks, deformities, closure issues, volume, insufficient (b)(4), leaks, (b)(4), discoloration, turbidity, other appearance defects).

我方鼓励采用适当的(b)(4)可见异物目视检查,以补充(b)(4)目视检查程序。(b)(4)方法应经过严格研究和确认,以评估其在各种条件、设备设置、容器密封件规格、缺陷类型、产品特性及其他变量下的能力和稳健性。此外,将(b)(4)异物检查用作辅助方法,并不能取代针对其他多种属性(例如裂纹、变形、密封件问题、装量、(b)(4)不足、泄漏、(b)(4)、变色、浑浊及其他外观缺陷)的(b)(4)目视检查需要。

It is important that any visible particulate contamination is appropriately evaluated and investigated. Visible particulates in injectable products should be avoided through appropriate preventive measures built into your design and production controls. When categorizing any visible particles, extrinsic or foreign matter should receive special attention, as it may indicate possible microbial contamination. Extrinsic or foreign particulate contamination should occur very infrequently, and trigger a thorough investigation and appropriate CAPA.

重要的是,任何可见异物污染均应得到适当评价和调查。注射剂中的可见异物,应通过设计和生产控制中内置的适当预防措施加以避免。在对任何可见粒子进行分类时,外源性或异物应特别关注,因为它可能提示存在微生物污染。外源性或异物污染应极少发生,一旦发生应触发彻底调查和适当的CAPA。

(b)(4) product operations should be designed to prevent particle contamination. Regarding (b)(4) products, it is essential that operations are designed and controlled to protect consumers from the risk of (b)(4) potentially harmful particles (b)(4). Microbes introduced (b)(4) can pose a serious risk to consumers. Irreversible damage, including (b)(4), can occur and, in some cases, may progress to life-threatening systemic infection.

(b)(4)产品操作的设计应能防止粒子污染。就(b)(4)产品而言,操作的设计和控制必须能够保护消费者免受(b)(4)潜在有害粒子(b)(4)的风险。(b)(4)引入的微生物可对消费者构成严重风险,可能造成不可逆损害(包括(b)(4)),某些情况下可发展为危及生命的全身性感染。

Additional Guidance on Aseptic Processing

无菌工艺的补充指南

See FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https://www.fda.gov/media/71026/download.

参见FDA指南文件《无菌工艺生产的无菌药品——现行药品生产质量管理规范》,以帮助你在采用无菌工艺生产无菌药品时满足CGMP要求:https://www.fda.gov/media/71026/download。

Quality Systems

质量体系

Your firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA guidances: Q8(R2) Pharmaceutical Development at https://www.fda.gov/media/71535/download, Q9(R1) Quality Risk Management at https://www.fda.gov/media/167721/download, and Q10 Pharmaceutical Quality System at https://www.fda.gov/media/71553/download.

你司质量体系不充分。有关建立和维持符合CGMP的质量体系的指南,参见FDA指南:Q8(R2)《药品研发》https://www.fda.gov/media/71535/download、Q9(R1)《质量风险管理》https://www.fda.gov/media/167721/download,以及Q10《药品质量体系》https://www.fda.gov/media/71553/download。

Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production operations, we found your QU is not enabled to exercise proper authority and/or has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.

本信中的重大发现表明,你司未按CGMP运行有效的质量体系。除生产运营缺乏有效管理监督外,我方还发现你司质量部门未被赋予行使适当权限的条件,和/或未充分履行其职责。高层管理应立即、全面地评估你公司的全球生产运营,以确保你司的体系、工艺和产品符合FDA要求。

Drug Production Suspended

药品生产暂停

We acknowledge your initial commitment to suspend production of your (b)(4) drugs at this facility for the U.S. market. You subsequently notified us of your decision to discontinue commercial manufacturing of product from the (b)(4) filling line to the U.S. market. In response to this letter, clarify whether you intend to resume manufacturing (b)(4) drugs for the U.S. market at this facility in the future.

我方注意到你司最初承诺暂停该设施(b)(4)药品供美国市场的生产。你司随后通知我方,决定停止(b)(4)灌装线产品对美国的商业生产。请在回复本信时澄清,你司今后是否打算恢复该设施(b)(4)药品供美国市场的生产。

If you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. If you resume CGMP activities, you are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In addition, based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit***1*** of your entire operation for CGMP compliance and evaluate the completion and efficacy of all corrective action and preventive action, before you pursue resolution of your firm’s compliance status with FDA.

如你司计划恢复任何受FD&C法案监管的生产运营,须在恢复药品生产运营前通知本办公室。如恢复CGMP活动,你司有责任解决所有缺陷和系统性缺陷,以确保具备持续符合CGMP的能力。此外,鉴于我方在你司发现的违规性质,你司应聘请符合21 CFR 211.34规定的合格顾问,协助你司满足CGMP要求。该合格顾问还应按脚注1对你司整个运营开展全面的六系统审计,评估CGMP符合性,并在你司寻求解决FDA合规状态之前,评价所有纠正与预防措施的完成情况和有效性。

Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.

聘请顾问并不免除你司遵守CGMP的义务。你司高层管理仍负责解决所有缺陷和系统性缺陷,以确保持续符合CGMP。

In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.

在向FDA提交的通知中,请提供整改摘要,以证明你司已适当完成所有CAPA。

Conclusion

结论

You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.

你司有责任对任何违规进行调查并确定根本原因,实施纠正和预防措施,以确保未来持续合规,使这些违规及其他违规不再发生。

FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.

在违规全部处理完毕且我方确认你司符合CGMP之前,FDA可能暂缓批准将你司列为药品生产商的新申请或补充申请。我方可能再次检查,以核实你司已完成针对各项违规的纠正措施。

Failure to address any violations may also result in the FDA refusing admission of articles manufactured at USV Private Limited, Dabhel, Daman, Dadra and Nagar Haveli and Dam, India, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).

未处理任何违规还可能导致FDA依据FD&C法案第801(a)(3)条(21 U.S.C. 381(a)(3))拒绝USV Private Limited(印度达德拉-纳加尔哈维利和达曼-第乌联邦属地达曼Dabhel)生产的物品进入美国。依据该条,疑似掺假的物品可被扣留或拒绝入境,因为其生产所用方法和控制措施似乎不符合FD&C法案第501(a)(2)(B)条(21 U.S.C. 351(a)(2)(B))所指的CGMP。

If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.

如你司正在考虑可能导致该设施所产药品供应中断的措施,FDA要求你司立即联系CDER药品短缺工作人员(drugshortages@fda.hhs.gov),以便FDA与你司共同研究使运营符合法律的最有效方式。联系药品短缺人员还可使你司履行依据21 U.S.C. 356C(b)报告药品生产停止或中断的义务,并使FDA能够尽快考虑为避免短缺、保护依赖你司产品的患者健康而可能需要采取的行动。

Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter.***2*** Identify your written response with FEI 3004086192 and ATTN: William Yang in the subject line of the email.

请在收到本信后十五(15)个工作日内将书面回复发送至 CDER-OC-OMQ-Communications@fda.hhs.gov(见脚注2)。请在邮件主题行注明 FEI 3004086192 及 ATTN: William Yang。

If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.

如果你司认为有信息可证明你司产品未违反FD&C法案和FDA法规,请一并提供供我方考虑。

FDA posts warning letters to www.FDA.gov.

FDA将警告信公布于 www.FDA.gov。

Sincerely, /S/ Francis Godwin, Director, Office of Manufacturing Quality, Office of Compliance, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

此致。签名:/S/ Francis Godwin(弗朗西斯·戈德温),主任,生产质量办公室,合规办公室,药品评价与研究中心,美国FDA

cc: Registered U.S. Agent, Vikas Yadav, Pharmavector LLC

抄送:美国注册代理人 Vikas Yadav,Pharmavector LLC

来源:制药经理人 · mp.weixin.qq.com

事件后续 · 2

查看事件全部